Skip to main content
letter
. 2021 Oct 7;92:102615. doi: 10.1016/j.bcmd.2021.102615

Table 1.

Characteristics of the patients.

#1 #2 #3 #4
Age (years) 27 63 39 24
Sex M M F M
Medical history Silent DM, hypertension, dyslipidemia Hashimoto's thyroiditis Silent
Previous autoimmune cytopenia No No Chronic ITP ITP, AIHA
Allergies None None None None
Vaccine received BNT162b2 mRNA (Pfizer) ChAdOx1-S (Vaxzevria) BNT162b2 mRNA (Pfizer) mRNA-1273 (Moderna)
Firs/second dose First dose First dose Second dose Second dose
Time from vaccination to ITP (days) 10 14 6 21
Symptoms Hematomas, epistaxis Hematomas, epistaxis Petechiae, ecchymosis Petechiae
PLT count nadir 1 × 109/L 2 × 109/L 1 × 109/L 2 × 109/L
Treatment IVIG - Prednisone - dexamethasone Prednisone IVIG – prednisone- eltrombopag-romiplostim IVIG – prednisone - IVIG
Response CR CR PR CR